🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Artificial Intelligence-Enabled Wearable Devices and Nocturnal Scratching in Mild Atopic Dermatitis #atopicdermatitis #AIdevices #dermatology #itchresearch pubmed.ncbi.nlm.nih.gov/39908036/

Excited about a device that both measures scratch based on finger movement and the sound of itch — and can optionally provide a haptic vibration when sensing scratch to stop it, even at night.  AP #AtopicDermatitis #Eczema #ArtificialIntelligence #AI #WearableTech #DigitalHealth

Managing Childhood and Adolescent Atopic Dermatitis in Primary Care: A US Expert Group Consensus #atopicdermatitis #dermatology #pediatricdermatology pubmed.ncbi.nlm.nih.gov/39950052/

Great to see some action in addressing the curtailing of science #StandUpForScience2025

Unmet Needs of Effective Advanced Systemic Therapies in Moderate-to-Severe Atopic Dermatitis Patients in the TARGET-DERM AD Registry #atopicdermatitis #dermatology pubmed.ncbi.nlm.nih.gov/39969951/

Integrated Efficacy and Safety Analysis of Abrocitinib in Adolescents With Moderate-to-Severe Atopic Dermatitis #atopicdermatitis #dermatology pubmed.ncbi.nlm.nih.gov/40028832/

Assessment of Alopecia Areata Disease Severity in Pediatric Patients (PDE15830) #pediatricdermatology #alopeciaareata #dermatology onlinelibrary.wiley.com

Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomized placebo-controlled PROTOSTAR study #pediatricdermatology #psoriasis #dermatology pubmed.ncbi.nlm.nih.gov/39708367/

Maximal Usage Trial of Tapinarof Cream 1% Once Daily in Pediatric Patients Down to 2 Years of Age with Extensive Atopic Dermatitis #atopicdermatitis #dermatology #pediatricdermatology pubmed.ncbi.nlm.nih.gov/40126804/

Low Infection Rates With Long-Term Dupilumab Treatment in Patients Aged 6 Months to 5 Years: An Open-Label Extension Study #pediatricdermatology #dermatology pubmed.ncbi.nlm.nih.gov/39529307/

Decision Aid for Pediatric Atopic Dermatitis #atopicdermatitis #pediatricdermatology #dermatology pubmed.ncbi.nlm.nih.gov/39921089/

Having a device that can measure TEWL remotely, continuously or as programmed by the investigator - and without perturbing a patient during sleep - is a major advance. #wearabledevices A non-contact wearable device for monitoring epidermal molecular flux pubmed.ncbi.nlm.nih.gov/40205217/

Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa #raredisease #epidermolysisbullosa #dermatology pubmed.ncbi.nlm.nih.gov/40220208/

Functional genotype classification groups distinguish disease severity in recessive dystrophic epidermolysis bullosa #rdeb #raredisease #epidermolysisbullosa #dermatology pubmed.ncbi.nlm.nih.gov/39790012/

FDA approves cell-sheet-based gene therapy for severe skin disease #raredisease #epidermolysisbullosa #dermatology #skinwound nature.com/articles/d4157…

New Review Alert: Deciding which patients with atopic dermatitis to prioritize for biologics and Janus kinase inhibitors #atopicdermatitis #biologics #jakinhibitors #dermatology #dermatologyresearch pubmed.ncbi.nlm.nih.gov/40368249/

Maximal Usage Trial of Tapinarof Cream 1% Once Daily in Pediatric Patients Down to 2 Years of Age with Extensive Atopic Dermatitis #atopicdermatitis #dermatology #pediatricdermatology pubmed.ncbi.nlm.nih.gov/40126804/

Efficacy and Safety of Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From TRuE-AD3, a Phase 3, Randomized Double-Blind Study #atopicdermatitis #dermatology #pediatricdermatology pubmed.ncbi.nlm.nih.gov/40378883/

An international multicenter, retrospective cohort study of 203 patients with pediatric androgenetic #alopecia #dermatology #pediatricdermatology pubmed.ncbi.nlm.nih.gov/39921108/